1st Annual Regen Med Investor Day
Platform to Bedside
Marc Hedrick, MD
President
Safe Harbor Statement
This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All
statements, other than statements of historical fact, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.
Such statements are based upon certain assumptions and assessments made by our management in light of
their experience and their perception of historical trends, current conditions, expected future developments
and other factors they believe to be appropriate.
The forward-looking statements included in this presentation involve known and unknown risks that relate to
Cytori’s future events or future financial performance and the actual results could differ materially from those
discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ
materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s
Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We
would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed
with the United States Securities and Exchange Commission for a more detailed description of these risks.
The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions
only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise
publicly any forward-looking statements contained in this presentation as a result of new information, future
events or changes in Cytori’s expectations.
Cytori Platform: Technology
Technology for cell
isolation, combination
with other factors,
storage and clinical
therapy
STEP 1 Harvest patient
tissue (100cc)
STEP 2 Separate &
Process
STEP 3 Deliver ADRCs to
Same Patient, ~1 hr.
Cytori Platform: Model
Goal: Leadership in Regenerative Medicine
Research &
Development
Basic
Science
Product
Development
CAPITAL
Regulatory
Approval
Device Approvals
Therapeutic
Approvals
Clinical
Use
Safety
Efficacy
Commercial
Self Pay
Reimbursement
PROFIT
Cytori Platform: Case Study
Gen One
Device
EU
Approval
EU
Breast
Pivotal
Japan
Breast
Pilot
Radiation
Injury, BARDA
Ischemia &
CV Trials
Sales
Other Approvals
& Applications
Cytori Cell Therapy:
US Government Contract
Discussions
Begin
2010
Award
Announcement
Fall, 2012
3 Objectives Trigger
Option 1 & 3
Q1, 2014
3 Proof-of-concept Objectives
Ongoing
Cell viability
Animal model POC
Next Gen device feasibility
$32.6 M Option 1
$23.4M Option 3
Commercial Acquisition at
BARDA’s Discretion
$45.5M Option 2
Option 1 Objective
Triggers Option 2
Q4, 2015
Pre-Award, White Papers,
Proposal, Negotiation
$4.7M Phase 1 Proof of Concept
Cytori Platform: Clinical Trials and Studies
43 total: 2 Cytori sponsored trials & 41 investigator studies
USA
1 EU
23 AP
13
EM
6
Soft Tissue: 18
Wound: 7
Ischemia: 2
Ortho/Sport: 8
Vital Organ: 8
Total: 43